Commentary: California's biotech firms could benefit from tax policy

Repealing California's single sales factor tax apportionment not only will revive a failed tax regulation that imposed penalties on biotech companies for creating jobs and economic growth in the state but also will stifle the development of promising treatments, BayBio President and CEO Matthew M. Gardner writes in this commentary piece. The adoption of the sales tax reform will help the state weather the recession and pay for key services, Gardner writes.

View Full Article in:

San Jose Mercury News (Calif.) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC